[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
High Institute for Research and Education in Transfusion Medicine::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Submission::
Contact us::
Site Facilities::
Commitment letter::
Ethics & Permissions::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Indexing
                        
..
:: Volume 19, Issue 4 (winter 2022) ::
Sci J Iran Blood Transfus Organ 2022, 19(4): 284-291 Back to browse issues page
Improvement of anticomplementary activity assay for the quality control of immunoglobulin product: an Iranian pilot scale study
S. Mohammadi Bidhendi , M. Bagheri , H. Khorsand Mohammadpour , S. Banazadeh , A.A. Pourfathollah , P. Kokhaei , A. Aghaie *
Keywords: Key words: Immunoglobulin, Quality Control, Plasma
Full-Text [PDF 379 kb]   (630 Downloads)     |   Abstract (HTML)  (841 Views)
Type of Study: Research | Subject: Blood Transfusion
Published: 2022/12/31
Full-Text:   (634 Views)
    References:
  1. Arumugham VB, Rayi A. Intravenous Immunoglobulin (IVIG). 2022 Jul 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
  2. Cohn EJ, Strong LE, Hughes W, Mulford D, Ashworth J, Melin Me, et al. Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids. J Am Chem Soc 1946; 68(3): 459-75.
  3. Bruton OC. Agammaglobulinemia. Pediatrics 1952; 9(6): 722-8.
  4. Farrugia A, Poulis P. Intravenous immunoglobulin: regulatory perspectives on use and supply. Transfus Med 2001; 11(2): 63-74.
  5. Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human γ-globulin. Vox Sang 1962; 7(2): 157-74.
  6. Buchacher A, Schluga P, Müllner J, Schreiner M, Kannicht C, Weinberger J. Anticomplementary activity of IVIG concentrates–important assay parameters and impact of IgG polymers. Vox Sang 2010; 98(3p1): e209-e18.
  7. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43(10): 1460-80.
  8. Ramasamy I, Tran E, Farrugia A. Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparations. Biologicals 1997; 25(1): 87-92.
  9. Prince A, Horowitz B, Horowitz M, Zang E. The development of virus-free labile blood derivatives--a review. Eur J Epidemiol 1987; 3(2): 103-18.
  10. European Pharmacopeia: Human normal immunoglobulin for intravenous administration. Strasbourg Cedex, France: European Pharmacopeia  6.3; 2009. p. 4166-8.
  11. European Pharmacopoeia. 10th ed. Council of Europe, 67075 Strasbourg Cedex, France: European Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM); 2019. p. 216-8.
  12. Krivykh M, Kornilova O, Bunyatyan N, Kudasheva ÉY. Optimization of the Conditions for Assay of the Anti-Complement Activity of Human Immunoglobulin Preparations for Intravenous Administration. Pharmaceutical Chemistry Journal 2015; 49(7): 473-6.
  13. Padmore RF. Hemolysis upon intravenous immunoglobulin transfusion. Transfus Apher Sci 2012; 46(1): 93-6.
  14. Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol Immunol 2008; 45(16): 4073-9.
  15. Eibl MM, Ahmad R, Wolf HM, Linnau Y, Gotz E, Mannhalter JW. A component of factor VIII preparations which can be separated from factor VIII activity down modulates human monocyte functions. Blood 1987; 69(4): 1153-60. 
  1. British Pharmacopoeia, Blood-related products, Normal Immunoglobulin for Intravenous Use.  British Pharmacopoeia (BP). IV2020. p. 613-5.
  2. WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser 1994; 840: 1-218.
  3. Miekka SI, Gozze I. Anticomplementary activity of human immunoglobulin G. I. Mechanism of the artifactual  increase  in    anticomplementary  activity of IgG during the assay. Vox Sang 1975; 29(2): 101-23.
  4. Krivykh MA, Kornilova OG, Bunyatyan ND,   Kudasheva  ÉY.   Optimization   of   the   Conditions for Assay of the Anti-Complement Activity of Human    Immunoglobulin Preparations for Intravenous Administration. Pharmaceutical Chemistry Journal 2015; 49(7): 473-6.












 
 


Sci J Iran Blood Transfus Organ 2022;19 (4): 284-291
 
Original Article
 
Improvement of anticomplementary activity assay for

the quality control of immunoglobulin product:
an Iranian pilot scale study

Mohammadi Bidhendi S.1, Bagheri M.1, Khorsand Mohammadpour H.2, Banazadeh S.3,
Pourfathollah A.A.4, Kokhaie P.5, Aghaie A.2

1Semnan University of Medical Sciences, Semnan, Iran
2Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
3Fardavar Companies Group, Tehran, Iran
4Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
5Karolinska University Hospital Solna, Stockholm, Sweden

Abstract
Background and Objectives
One of the side effects of immunoglobulin administration is the activation of the complement system related to the high concentration of aggregates/large polymers in the production process. Measuring anticomplementary activity (ACA) is important in pharmaceutical quality control and is a criterion of spontaneous activation of complement system in immunoglobulin products prepared from human plasma.

Materials and Methods
In this experimental study, ACA was established based on the European Pharmacopoeia (EP) and ACA was measured and compared in two immunoglobulin products obtained by two modified Cohn's methods A or B. The measurement is based on the ability of immunoglobulin for binding to complement and prevent the lysis of sensitized sheep red blood cells (SRBC). Therefore, immunoglobulin was incubated with guinea pig complement and then the remaining complement was titrated by CH50 method and expressed as a percentage.

Results
ACA values in two products in the two methods of A and B and in two consecutive days and eight times each day were determined to be 0.486 ± 0.08 and 0.466 ± 0.07 CH50/mg protein, respectively; compared to commercial IVIG (Biotest Company) that was 0.486 ± 0.07. ACA activity was measured as less than ≤ 1 CH50 ⁄mg IgG, which was in accordance with the requirements of the pharmacopoeia.

Conclusions 
Quantitative and qualitative immunoglobulin measurements are as valuable as research and development in plasma purification processes. With the launch of the ACA test, ACA analysis has become possible during the production process as well as in the validation stages of immunoglobulin products.

Key words: Immunoglobulin, Quality Control, Plasma


Received: 22 Aug 2022
Accepted:  1 Nov 2022


Correspondence: Aghaie A., PhD of Immunology. Associate Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 82052183; Fax: (+9821) 88601599
E-mail: aghaie.a@gmail.com
 
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mohammadi Bidhendi S, Bagheri M, Khorsand Mohammadpour H, Banazadeh S, Pourfathollah A, Kokhaei P et al . Improvement of anticomplementary activity assay for the quality control of immunoglobulin product: an Iranian pilot scale study. Sci J Iran Blood Transfus Organ 2022; 19 (4) :284-291
URL: http://bloodjournal.ir/article-1-1460-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 19, Issue 4 (winter 2022) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.04 seconds with 39 queries by YEKTAWEB 4704